Next Article in Journal
Editorial of the Special Issue: Antisense Therapies
Next Article in Special Issue
A New Role for Vitamin D: The Enhancement of Oncolytic Viral Therapy in Pancreatic Cancer
Previous Article in Journal
Intravenous Infusion of Nucleated Peripheral Blood Cells Restores Fertility in Mice with Chemotherapy-Induced Premature Ovarian Failure
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessReview

Recombinant Viruses for Cancer Therapy

1
Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia
2
School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, Leicestershire LE12 5RD, UK
3
Department of Microbiology and Immunology, University of Nevada, Reno, NV 89557, USA
*
Author to whom correspondence should be addressed.
Biomedicines 2018, 6(4), 94; https://doi.org/10.3390/biomedicines6040094
Received: 14 August 2018 / Revised: 17 September 2018 / Accepted: 20 September 2018 / Published: 25 September 2018
(This article belongs to the Special Issue Viruses in Cancer and Therapy)
  |  
PDF [732 KB, uploaded 25 September 2018]
  |  

Abstract

Recombinant viruses are novel therapeutic agents that can be utilized for treatment of various diseases, including cancers. Recombinant viruses can be engineered to express foreign transgenes and have a broad tropism allowing gene expression in a wide range of host cells. They can be selected or designed for specific therapeutic goals; for example, recombinant viruses could be used to stimulate host immune response against tumor-specific antigens and therefore overcome the ability of the tumor to evade the host’s immune surveillance. Alternatively, recombinant viruses could express immunomodulatory genes which stimulate an anti-cancer immune response. Oncolytic viruses can replicate specifically in tumor cells and induce toxic effects leading to cell lysis and apoptosis. However, each of these approaches face certain difficulties that must be resolved to achieve maximum therapeutic efficacy. In this review we discuss actively developing approaches for cancer therapy based on recombinant viruses, problems that need to be overcome, and possible prospects for further development of recombinant virus based therapy. View Full-Text
Keywords: recombinant viruses; virus-based vaccines; oncolytic viruses; gene therapy; cell therapy; chimeric antigen receptor (CAR) T-cell therapy recombinant viruses; virus-based vaccines; oncolytic viruses; gene therapy; cell therapy; chimeric antigen receptor (CAR) T-cell therapy
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Chulpanova, D.S.; Solovyeva, V.V.; Kitaeva, K.V.; Dunham, S.P.; Khaiboullina, S.F.; Rizvanov, A.A. Recombinant Viruses for Cancer Therapy. Biomedicines 2018, 6, 94.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top